Drug Profile
Research programme: erythropoietin long-acting - OPKO Health
Alternative Names: EPO-CTP; MOD-7023Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Modigene
- Developer OPKO Health
- Class Erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Anaemia in USA (Parenteral, Injection)
- 29 Aug 2013 PROLOR Biotech has been acquired by OPKO Health
- 10 Jan 2013 Preclinical development is ongoing